Compare Eli Lilly And Co (LLY) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs US Bancorp — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while US Bancorp trades at $57.1 (market cap $88.86B). The key difference: Eli Lilly And Co is far larger — about 11.7× US Bancorp's market cap, and US Bancorp pays the higher dividend (3.79%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and US Bancorp for 97 Days on average.
| LLY | USB | |
|---|---|---|
Market Cap | $1.04T | $88.86B |
Volume | 3,064,878 | 8,869,993 |
Sector | Health | Financials |
52-Week High | $1.28K | $65.42 |
52-Week Low | $799.57 | $45.28 |
Typical Hold Time | 93 Days | 97 Days |
Enterprise Value | $1.09T | $118.35B |
Dividend Yield | 0.59% | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
U.S. Bancorp (USB) trades at $57.08, up 1.62% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 11.38 and net income margin of 27.61%, supported by three consecutive quarterly earnings beats. Recent news highlights dividend increases and positive Q3 2026 revenue expectations, though technical indicators suggest near-term pressure with key support at $55.
USB presents a compelling value opportunity with analyst consensus price target of $69.94 (22.5% upside) and 51% buy ratings. Risks include regulatory changes and interest rate sensitivity, but strong profitability metrics and institutional confidence support long-term growth prospects in the regional banking sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
